With two approved and about 30 in clinical development, bispecific antibodies are at last moving into the therapeutic mainstream.
We sat down with Genetech Senior Director of Antibody Engineering Dr. Paul Carter for a brief look at where the field is going.
In this podcast interview for Inside Antibody Engineering, Dr. Carter discusses:
• Choosing a format
• New applications
• Emerging routes of administration and more...
Listen to the podcast or download a transcript here!
Editor’s note: Dr. Paul Carter will co-chair a track on new technologies and applications for bispecific antibodies at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.
Click here for an agenda
Or for more information visit: www.ibclifesciences.com/antibodyeng
(Ps. SAVE $100 when you register with code D15172BLOG!)
ABOUT THE AUTHOR/INTERVIEWER
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at email@example.com. Follow him @mdrezz.
Share this article with your social network, just click below to share now!